Andrew Polovin serves as Executive Vice President, General Counsel, and Secretary at Tempus AI, Inc. (NASDAQ: TEM), a pioneering AI-driven precision medicine company revolutionizing healthcare through data analytics and genomic sequencing. In this multifaceted role, he leads the company's global legal strategy, overseeing corporate governance, regulatory compliance, mergers and acquisitions, intellectual property protection, and risk management. Polovin has been instrumental in steering Tempus through its high-growth phase, including its landmark initial public offering in June 2024, ensuring robust legal frameworks that support the company's mission to personalize cancer care and expand into new therapeutic areas. Prior to joining Tempus in September 2021, Polovin was a partner in the corporate practice group at Sidley Austin LLP, where he specialized in complex mergers and acquisitions, securities offerings, and strategic counseling for technology, healthcare, and financial services clients. His earlier career included a stint as an associate at Cravath, Swaine & Moore LLP and roles at Citadel Investment Group, where he developed deep expertise in securities law, venture capital, and cross-border transactions. Polovin's achievements include advising on multibillion-dollar deals and navigating intricate regulatory landscapes, earning him recognition as a leading lawyer in his field. A graduate of Northwestern University Pritzker School of Law (J.D.) and the University of Michigan (B.A.), Polovin brings a blend of legal acumen and business savvy to Tempus. Under his guidance, the company has fortified its position as an innovator in AI-healthcare integration, forging key partnerships and securing vital IP assets while maintaining compliance amid rapid expansion.